Department of Medical Microbiology and Parasitology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia.
Microb Pathog. 2010 Nov;49(5):211-6. doi: 10.1016/j.micpath.2010.06.001. Epub 2010 Jun 15.
Cholera caused by the O139 serogroup still remains a public health concern in certain regions of the world and the existing O1 vaccines do not cross-protect cholera caused by this serogroup. An aminolevulinic acid (ALA) auxotroph vaccine candidate against the O139 serogroup, designated as VCUSM2, was recently developed. It was found to be immunogenic in animal model studies but showed mild reactogenic effects due to the presence of two intact copies of Vibrio cholerae toxin (CTX) genetic element. In the present study we have modified the ctx operon by systematic allelic replacement methodology to produce a mutant strain, designated as VCUSM14. This strain has two copies of chromosomally integrated and mutated ctxA gene, encoding immunogenic but not toxic cholera toxin A subunit (CT-A). The amino acids arginine and glutamic acid at position 7th and 112th, respectively, in CT-A of VCUSM14 were substituted with lysine (R7K) and glutamine (E112Q), respectively. Two copies of the ace and zot genes present in the ctx operon were also deleted. Cholera toxin-ELISA using GM1 ganglioside showed that the both wild type CT and mutated CT were recognized by anti-CT polyclonal antibodies. VCUSM14 produced comparatively less amount of antigenic cholera toxin when compared to the VCUSM2 and Bengal wild type strain. VCUSM14 did not elicit fluid accumulation when inoculated into rabbit ileal loops at doses of 10(6) and 10(8) CFU. The colonization efficiency of VCUSM14 was one log lower than the parent strain, VCUSM2, which can be attributed to the ALA auxotrophy and less invasive properties of VCUSM14. VCUSM14, thus a non-reactogenic auxotrophic vaccine candidate against infection by O139 V. cholerae.
O139 血清群霍乱弧菌仍然是世界某些地区的公共卫生关注点,现有的 O1 疫苗不能交叉保护该血清群引起的霍乱弧菌感染。最近开发了一种针对 O139 血清群的氨基乙酰丙酸(ALA)营养缺陷型疫苗候选物,命名为 VCUSM2。在动物模型研究中发现它具有免疫原性,但由于存在两个完整的霍乱弧菌毒素(CTX)遗传元件,它表现出轻微的致反应性效应。在本研究中,我们通过系统等位基因替换方法修饰了 ctx 操纵子,产生了一个突变株,命名为 VCUSM14。该菌株有两个整合和突变 ctxA 基因的染色体拷贝,编码免疫原性但无毒性的霍乱毒素 A 亚单位(CT-A)。CT-A 的第 7 位和第 112 位的精氨酸和谷氨酸分别被赖氨酸(R7K)和谷氨酰胺(E112Q)取代。CTX 操纵子中存在的两个 ace 和 zot 基因也被删除。使用 GM1 神经节苷脂的霍乱毒素 ELISA 表明,野生型 CT 和突变型 CT 均被抗 CT 多克隆抗体识别。与 VCUSM2 和孟加拉野生型菌株相比,VCUSM14 产生的抗原性霍乱毒素量相对较少。当以 10(6)和 10(8)CFU 的剂量接种到兔回肠环中时,VCUSM14 没有引起液体积累。VCUSM14 的定植效率比亲本菌株 VCUSM2 低一个对数级,这归因于 VCUSM14 的 ALA 营养缺陷和侵袭性较低。因此,VCUSM14 是一种针对 O139 霍乱弧菌感染的非致反应性营养缺陷型疫苗候选物。